Skip to main content
. 2019 Oct 3;4(19):e128713. doi: 10.1172/jci.insight.128713

Figure 5. RANKL blockade with denosumab decreases disease-associated bone loss.

Figure 5

(A) Experimental design: HTLV-1–infected humanized mice were treated with vehicle (PBS) or denosumab twice weekly for 3 weeks from day 3 before sacrifice. (B) μCT analysis used to calculate trabecular bone to tissue volume ratio (BV/TV) on day 21. (C) Representative 3-D reconstruction images of tibial trabecular bone in a denosumab treated mouse compared with vehicle control. Scale bar: 300 μm. (D) μCT analysis used to calculate trabecular bone mineral density (BMD) on day 21. (E) Spleen weight measured on day 21. (F) Flow cytometry of human CD45+ and (G) human CD4+ T cells from PBMC obtained before infection (day –1) and on days 10 and 20 after infection. Error bars in this figure represent ± SEM. *P < 0.05; **P < 0.01 (2-tailed distribution, homoscedastic Student’s t test).